Promoter methylations of RASSF1A and p16 is associated with clinicopathological features in lung cancers.

MLA

Ji-Chang Han, et al. “Promoter Methylations of RASSF1A and P16 Is Associated with Clinicopathological Features in Lung Cancers.” Journal of Cancer Research & Therapeutics, vol. 12, no. 1, Jan. 2016, pp. 340–49. EBSCOhost, https://doi.org/10.4103/0973-1482.154926.

APA

Ji-Chang Han, Feng Xu, Na Chen, Guan-Bin Qi, Yu-Ju Wei, Hong-Bing Li, Yi-Jie Zhang, Jing-He Li, Xiu-Li Wang, Wen Xu, Xiao-Feng Li, Li-Fang Jin, Jiao-Yuan Jia, Zhong-Sen Ma, Han, J.-C., Xu, F., Chen, N., Qi, G.-B., Wei, Y.-J., & Li, H.-B. (2016). Promoter methylations of RASSF1A and p16 is associated with clinicopathological features in lung cancers. Journal of Cancer Research & Therapeutics, 12(1), 340–349. https://doi.org/10.4103/0973-1482.154926

Chicago

Ji-Chang Han, Feng Xu, Na Chen, Guan-Bin Qi, Yu-Ju Wei, Hong-Bing Li, Yi-Jie Zhang, et al. 2016. “Promoter Methylations of RASSF1A and P16 Is Associated with Clinicopathological Features in Lung Cancers.” Journal of Cancer Research & Therapeutics 12 (1): 340–49. doi:10.4103/0973-1482.154926.